Fig. 2

Targeting miR-181a increased olaparib sensitivity and increased STING protein levels. A Quantification of miR-181a levels by RT-qPCR comparing HCC1937 OlaR cell line treated with miR-181a-hairpin inhibitor (miR-inh, 10 nM, 25 nM, and 50 nM) or with miR hairpin inhibitor negative control (CTRL) in HCC1937-OlaR cell line (One-way ANOVA). B Cell viability assays comparing miR-181a-inhibitor and miR hairpin inhibitor negative control (CTRL) in HCC1937-OlaR and HCC1395-OlaR cell lines (two-way ANOVA and Sidak’s multiple comparisons test). C. Drug sensitivity assays comparing miR-181a-inhibitor and miR hairpin inhibitor negative control (CTRL) in HCC1937-OlaR and HCC1395-OlaR cell lines, treated with different concentrations of olaparib (two-way ANOVA and Sidak’s multiple comparisons test). D Quantification of Western blotting analysis for STING and β-actin (loading control) comparing HCC1937 OlaR and HCC1395 OlaR cell lines treated with miR-181a-inhibitor or miR hairpin inhibitor negative control (CTRL). *p < 0.05, **p < 0.01, ***p < 0.001. Cell viability assays were performed in triplicates